X
[{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Silence Therapeutics"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Quell Therapeutics"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$156.0 million","upfrontCash":"Undisclosed","newsHeadline":"Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Quell Therapeutics"},{"orgOrder":0,"company":"Allergy Therapeutics","sponsor":"AGC Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Allergy Therapeutics"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,024.0 million","upfrontCash":"$20.0 million","newsHeadline":"Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Silence Therapeutics"},{"orgOrder":0,"company":"MiroBio","sponsor":"Medicxi","pharmaFlowCategory":"D","amount":"$97.0 million","upfrontCash":"Undisclosed","newsHeadline":"MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"MiroBio"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Funds will primarily be used to advance MiroBio’s two lead antibody candidates into clinical trials and obtain safety and efficacy data in patients with autoimmune diseases. MB272 and MB151 are differentiated, precision-engineered checkpoint receptor agonists for BTLA & PD-1.
Lead Product(s):
MB272
Therapeutic Area: Immunology
Product Name: MB272
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Medicxi
Deal Size: $97.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
June 29, 2022
Details:
Under the terms of the agreement, AGC Biologics is supporting the manufacturing and testing of Allergy Therapeutics’ VLP Peanut vaccine candidate, providing VLP material for Phase I supply.
Lead Product(s):
VLP Peanut
Therapeutic Area: Immunology
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Vaccine
Partner/Sponsor/Collaborator:
AGC Biologics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
March 31, 2022
Details:
Under the collaboration, Silence is responsible for executing the development program for SLN501 until the end of 1 phase I, after which Mallinckrodt will assume responsibility for clinical development and global commercialization.
Lead Product(s):
SLN501
Therapeutic Area: Immunology
Product Name: SLN501
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Mallinckrodt Pharmaceuticals
Deal Size: $2,024.0 million
Upfront Cash: $20.0 million
Deal Type: Collaboration
March 23, 2022
Details:
Proceeds to be used to fund clinical development of QEL-001 in liver transplantation, to accelerate development of its product pipeline across transplantation, neuroinflammatory and autoimmune diseases, and enhance its multi-modular engineered Treg platform.
Lead Product(s):
QEL-001
Therapeutic Area: Immunology
Product Name: QEL-001
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Jeito Capital
Deal Size: $156.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
November 29, 2021
Details:
The QEL-001 CAR is specific for HLA-A2, which localizes the activity of the CAR-Tregs to the site of the transplanted organ in HLA-A2 mismatch liver transplant patients (i.e. HLA-A2 negative recipients who received an HLA-A2 positive donor liver).
Lead Product(s):
Multi-modular Engineered Treg Cell Therapy
Therapeutic Area: Immunology
Product Name: QEL-001
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 27, 2021
Details:
The milestone relates to pre-clinical development work on the SLN500 C3 targeting program, highlighting the successful ongoing collaboration between the two companies.
Lead Product(s):
SLN501
Therapeutic Area: Immunology
Product Name: SLN501
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Mallinckrodt Pharmaceuticals
Deal Size: $2,020.0 million
Upfront Cash: $20.0 million
Deal Type: Collaboration
April 28, 2021